A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

This first-in-human study tests a new experimental drug, LY3954068, in people with early symptomatic Alzheimer's disease to evaluate its safety, how it behaves in the body, and early signs of whether it may slow disease progression. **You may be eligible if...** - You have experienced gradual memory decline for at least 6 months - Your memory and thinking tests show mild impairment (MMSE score 18–30, CDR score 0.5–1.0) - A brain scan (PET) confirms the presence of tau protein — a hallmark of Alzheimer's - You have a study partner (such as a family member or friend) who spends at least 10 hours a week with you and can attend appointments - You meet the BMI requirements (18–40 kg/m²) **You may NOT be eligible if...** - You have other serious medical conditions (heart, liver, kidney, lung, or neurological disease other than Alzheimer's) - You are allergic to flortaucipir (the PET scan tracer used) - You have a contraindication to MRI (such as a metal implant or claustrophobia) - Your life expectancy is less than 24 months Talk to your doctor to see if this trial is right for you.